Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This three-arm study will evaluate the efficacy and safety of various dosing regimens of MMF
combined with various dosing regimens of calcineurin inhibitor (CNI), either cyclosporine or
tacrolimus, in participants who have undergone kidney transplantation. Participants will be
randomized to one of three dosing regimens to receive concentration-controlled MMF with
reduced CNI, concentration-controlled MMF with standard CNI, or fixed-dose MMF with standard
CNI. Participants will be followed for 20-24 months after randomization.